NCT05444894View on ClinicalTrials.gov

EDIT-301 for Autologous Hematopoietic Stem Cell Transplant (HSCT) in Participants With Transfusion-Dependent Beta Thalassemia (TDT)

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

April 29, 2022

Primary Completion Date

September 30, 2025

Study Completion Date

December 31, 2025

Conditions
Transfusion Dependent Beta ThalassemiaHemoglobinopathiesThalassemia MajorThalassemia Intermedia
Interventions
GENETIC

EDIT-301

Administered by intravenous infusion after myeloablative conditioning with busulfan.

Trial Locations (8)

10032

Columbia University Medical Center - Department of Pediatrics, New York

Columbia University Medical Center, New York

19104

Children's Hospital of Philadelphia, Philadelphia

37203

Tristar Medical Group Children's Specialists/Sarah Cannon Center for Blood Cancers, Nashville

44195

Cleveland Clinic, Cleveland

55410

University of Minnesota, Minneapolis

94609

University of California San Francisco, Oakland

M5G 2M9

Princess Margaret Cancer Centre-University Health Network, Toronto

Sponsors
All Listed Sponsors
lead

Editas Medicine, Inc.

INDUSTRY